HANGZHOU TIGERMED CO. H 1 Asset Resilience Ratio

Latest as of March 2026: 0.11%

HANGZHOU TIGERMED CO. H 1 asset resilience ratio. HANGZHOU TIGERMED CO. H 1 (5HZ1) has an Asset Resilience Ratio of 0.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of HANGZHOU TIGERMED CO. H 1 to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€32.71 Million
≈ $38.24 Million USD Cash + Short-term Investments

Total Assets

€28.80 Billion
≈ $33.67 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of HANGZHOU TIGERMED CO. H 1 (2021–2025)

Asset resilience ratio of HANGZHOU TIGERMED CO. H 1 from 2021 to 2025. This chart shows how HANGZHOU TIGERMED CO. H 1's Asset Resilience Ratio has changed over time. Read total liabilities of HANGZHOU TIGERMED CO. H 1 for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down HANGZHOU TIGERMED CO. H 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 5HZ1 asset base.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €32.71 Million 0.11%
Total Liquid Assets €32.71 Million 0.11%

Asset Resilience Insights

  • Limited Liquidity: HANGZHOU TIGERMED CO. H 1 maintains only 0.11% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

HANGZHOU TIGERMED CO. H 1 Industry Peers by Asset Resilience Ratio

Compare HANGZHOU TIGERMED CO. H 1's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Lonza Group AG
SW:LONN
Diagnostics & Research 3.04%
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
Diagnostics & Research 13.43%
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
Cowealth Medical China Co.Ltd.
SHG:603122
Diagnostics & Research 2.25%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Scope Fluidics SA
WAR:SCP
Diagnostics & Research 16.51%

HANGZHOU TIGERMED CO. H 1 Asset Resilience Ratio by Year (2021–2025)

HANGZHOU TIGERMED CO. H 1 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for HANGZHOU TIGERMED CO. H 1.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.21% €59.46 Million
≈ $69.51 Million
€28.36 Billion
≈ $33.15 Billion
-0.05pp
2024-12-31 0.26% €74.85 Million
≈ $87.51 Million
€28.67 Billion
≈ $33.52 Billion
+0.12pp
2023-12-31 0.14% €42.14 Million
≈ $49.26 Million
€29.68 Billion
≈ $34.70 Billion
+0.05pp
2022-12-31 0.09% €24.95 Million
≈ $29.16 Million
€27.45 Billion
≈ $32.09 Billion
-0.03pp
2021-12-31 0.12% €29.18 Million
≈ $34.11 Million
€23.74 Billion
≈ $27.76 Billion
--
pp = percentage points

About HANGZHOU TIGERMED CO. H 1

F:5HZ1 Germany Diagnostics & Research
Market Cap
$604.57 Million
€517.12 Million EUR
Market Cap Rank
#10957 Global
#1279 in Germany
Share Price
€4.20
Change (1 day)
-0.94%
52-Week Range
€3.22 - €5.85
All Time High
€11.40
About

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more